paroxetine has been researched along with Anxiety Disorders in 149 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 25 (16.78) | 18.2507 |
| 2000's | 86 (57.72) | 29.6817 |
| 2010's | 32 (21.48) | 24.3611 |
| 2020's | 6 (4.03) | 2.80 |
| Authors | Studies |
|---|---|
| Gasparyan, A; Manzanares, J; Navarrete, F; Navarro, D | 1 |
| Chen, GY; Chen, L; Jin, Q; Li, J; Liu, XY; Liu, Y; Song, YH; Wu, XY; Wu, ZY; Zhao, X | 1 |
| Cattaneo, CI; De Berardis, D; Fornaro, M; Martinotti, G; Ressico, FV; Vieta, E | 1 |
| Dolzhenko, AV; Hadi, MA; Jalal, Z; Khan, TM; Yap, WS | 1 |
| Ahmed, RS; Dutt, R; Shankar, N; Srivastava, S; Yadav, A | 1 |
| Albrechtsen, A; Buller, R; Eriksson, H; Hobart, M; Lindgreen, S; Moltke, I; Nøhr, AK | 1 |
| Arranz, B; Arrojo, M; Becoña, E; Bernardo, M; Castells, X; Cunill, R; Flórez, G; Fonseca, F; Garriga, M; Goikolea, JM; González-Pinto, A; López, A; Sáiz, PA; San, L; Tirado-Muñoz, J; Torrens, M; Zorrilla, I | 1 |
| Dienel, A; Gastpar, M; Kasper, S; Möller, HJ; Müller, WE; Schläfke, S; Volz, HP | 2 |
| Bahto, A; Delić, D; Džubur Kulenović, A; Hadžimuratović, A; Halilović, Z; Kapo, B; Mašnić, H; Memić Serdarević, A | 1 |
| Alag, P; Balasubramaniam, M; Gupta, A; Gupta, S; Joshi, P; Maher, S; Tampi, D; Tampi, RR; Young, J | 1 |
| Bernstein, GA; Book, SW; Kushner, MG; Miller, PM; Randall, CL; Randall, PK; Smith, JP; Specker, SM; Thomas, SE | 1 |
| Alfarano, E; Candelli, C; Carabellese, F; Catanesi, R; La Tegola, D | 1 |
| Cao, L; Chen, J; Fang, Y; Hong, W; Peng, D; Wu, Z; Yuan, C; Zhang, C | 1 |
| De Ronchi, D; Gibiino, S; Mori, E; Serretti, A | 1 |
| Baltes, BB; Grekin, ER; Kirsch, I; Loree, AM; Sugarman, MA | 1 |
| Akil, H; Clinton, SM; Cohen, JL; Fant, AD; Glover, ME; Jackson, NL; Pugh, PC | 1 |
| Akindipe, TO; Ipser, JC; Sager, C; Stein, DJ; Wilson, D | 1 |
| Olgiati, P; Serretti, A | 1 |
| Argyropoulos, SV; Bell, CJ; Hood, SD; Nutt, DJ | 1 |
| Dubois, O; Galinowski, A; Germain, C; Olié, JP; Salamon, R; Vaugeois, C | 1 |
| Dernovsek, MZ; Sajovic, M; Tavcar, R | 1 |
| Amiel, JM; Coplan, JD; Mao, X; Mathew, SJ; Price, RB; Shungu, DC; Smith, EL | 1 |
| Andreescu, C; Begley, AE; Lenze, EJ; Mazumdar, S; Mulsant, BH; Reynolds, CF; Wetherell, JL | 1 |
| Brock, J; Cappelleri, JC; Feltner, DE; Harness, J; Morlock, R; Sambunaris, A | 1 |
| Krulewicz, S; Mannelli, P; Marks, DM; Masand, PS; Pae, CU; Patkar, AA; Peindl, K | 1 |
| Barrett, PS; Carpenter, DJ; Davies, JT; Fong, R; Horrigan, JP; Kraus, JE | 1 |
| Gale, CK; Millichamp, J | 1 |
| Dubois, O | 1 |
| Sussman, N | 1 |
| Gehlert, DR; Iyengar, S; Kielbasa, W; Marek, G; Mozley, D; Peng, X; Tauscher, J; Vandenhende, F | 1 |
| Haraguchi, K; Ieiri, I; Imuta, N; Kobayashi, D; Koyama, S; Mine, K; Murata, Y; Nishimura, R | 1 |
| Boerner, RJ | 1 |
| Banwarth, B; Dubois, O; Galinowski, A; Germain, C; Mouaffak, F; Olié, JP; Poirier, MF; Salamon, R; Vaugeois, C | 1 |
| LeBlanc, SR; Ovanessian, MM; Parikh, SV | 1 |
| Feltner, D; Morlock, RJ; Williams, VS | 1 |
| Spinhoven, P; Van der Does, AJ; Van Dijk, E; Van Rood, YR | 1 |
| Audi, EA; Graeff, FG; Roncon, CM; Sela, VR; Zangrossi, H | 1 |
| Borukaev, RR; Budtueva, FS; Chakhava, VO | 1 |
| Chauvet-Gélinier, JC | 1 |
| Cho, HB; Jeong, HS; Jung, JY; Kim, J; Kim, JE; Kim, TS; Lyoo, IK; Shin, E; Yoon, SJ | 1 |
| Balhara, YP; Deshpande, SN; Verma, R | 1 |
| Knapp, LE; Miceli, JJ; Ramey, TS; Rickels, K; Shiovitz, TM; Weaver, JJ | 1 |
| Guyatt, GH; Ioannidis, JP; Mills, EJ; Puhan, MA; Schünemann, HJ; Thorlund, K | 1 |
| Ding, JY; Wang, T; Xiao, SR; Xu, GX; Zeng, Y | 1 |
| Schruers, KR; Schutters, SI; van Megen, HJ; Van Veen, JF; Westenberg, HG | 1 |
| Beeské, S; Griebel, G; Stahl, SM | 1 |
| Berard, RM | 1 |
| Anderson, AP; Rademacher, DJ; Steinpreis, RE | 1 |
| Metzl, JM | 1 |
| Ferguson, JM; Lydiard, RB; Thase, ME; Wilcox, CS | 1 |
| Amador, XF; Baldini Rossi, N; Cassano, GB; Cassano, P; Dell'Osso, L; Pini, S; Savino, M | 1 |
| Thase, ME; Trivedi, M | 1 |
| Rickels, K; Rynn, M | 1 |
| Krishnan, R; Ranga, K | 1 |
| Holsboer, F; Keck, ME; Landgraf, R; Müller, MB; Ohl, F; Toschi, N; Uhr, M; Welt, T; Wigger, A | 1 |
| Gorman, JM | 2 |
| Green, B | 1 |
| Bellew, K; Iyengar, M; McCafferty, J; Rickels, K; Sheehan, D; Zaninelli, R | 1 |
| Bourin, M | 1 |
| Kawashima, T; Yamada, S | 1 |
| Bryson, H; Hewett, K; Iyengar, MK; Jokinen, RH; Lepola, UM; Nordera, G; Stocchi, F | 1 |
| Nemeroff, CB | 1 |
| Kilts, C | 1 |
| Wagner, KD | 1 |
| Golden, RN | 1 |
| Borgeat, F; Hättenschwiler, J; Khazaal, Y; Mattia, M; Stankovic, M; Zullino, DF | 1 |
| Dew, MA; Houck, P; Lenze, EJ; Mulsant, BH; Pollock, BG; Reynolds, CF; Shear, MK | 1 |
| Rosenthal, M | 1 |
| Bramley, T; Eaddy, M; Regan, T | 1 |
| Bang, LM; Keating, GM | 1 |
| Bellew, K; Rickels, K; Rynn, MA; Snyderman, SH | 1 |
| Andrews, G; Carter, R; Donnelly, M; Haby, MM; Heuzenroeder, L; Mihalopoulos, C; Rossell, R; Vos, T | 1 |
| Allgulander, C; Dahl, AA; Emilien, G; Lepola, U; Mangano, R; Sjödin, I; Zhang, J | 1 |
| Corral, M; Milis, L; Misri, S; Reebye, P | 1 |
| Lahmann, C; Leiberich, P; Loew, T; Mitterlehner, F; Nickel, C; Nickel, M; Rother, W; Tritt, K | 1 |
| Ballenger, JC | 1 |
| Ball, SG; Goddard, AW; Kuhn, A; Shekhar, A; Wall, D | 1 |
| Addington, S; Dichter, GS; Freid, CM; Shelton, RC; Tomarken, AJ | 1 |
| Cunha, A; Gazalle, FK; Kapczinski, F; Lima, MS; Schmitt, R; Souza, J | 1 |
| Harrison, D; Meng, F; Mullins, CD; Shaya, FT; Wang, J | 1 |
| Bennett, M; Mancini, C; Patterson, B; Van Ameringen, M | 1 |
| Cyranowski, JM; Fagiolini, A; Frank, E; Kupfer, DJ; Scott, J; Shear, MK; Swartz, H | 1 |
| Andersen, EW; Lader, M; Stein, DJ | 1 |
| Creed, F; Fernandes, L; Guthrie, E; Ratcliffe, J; Read, N; Rigby, C; Thompson, DG; Tomenson, B | 1 |
| Cantoni, A; Fontò, S; Giannelli, MR; Maggini, C; Marchesi, C | 2 |
| Eaddy, MT; Mauch, RP; Shah, MB; Sheehan, DV | 1 |
| Eaddy, MT; Keene, MS; Nelson, WW; Sarnes, MW | 1 |
| Bremner, JD; Foa, EB; Mayberg, HS; Nemeroff, CB; North, CS; Stein, MB | 1 |
| Christi, JA; Perera, P; Pitts, CD; Roy-Byrne, PP | 1 |
| Baldwin, DS; Lader, M; Montgomery, SA; Nil, R | 1 |
| Lang, AE; Voon, V | 1 |
| McClendon, J | 1 |
| Duff, D; Iyengar, M; Rickels, K; Rynn, M | 1 |
| Bailey, JE; Diaper, A; Kendrick, A; Nutt, DJ; Potokar, JP | 1 |
| Davidson, JR | 1 |
| Bron, MS; Meng, F; Mullins, CD; Shaya, FT; Wang, J | 1 |
| Bahk, WM; Chae, JH; Jun, TY; Kim, TS; Pae, CU; Rhee, WI; Yoon, SJ | 1 |
| Baldwin, DS; Huusom, AK; Maehlum, E | 1 |
| Baldwin, DS; Despiegel, N; Drost, PB; Hemels, ME; Jørgensen, TR; Stein, DJ | 1 |
| Ahn, SC; Choi, TK; Lee, SH; Lee, YJ; Suh, SY; Yook, KH | 1 |
| Andreescu, C; Cyranowski, JM; Dombrovski, AY; Houck, PR; Lenze, EJ; Mazumdar, S; Mulsant, BH; Reynolds, CF | 1 |
| Arban, R; Atkinson, PJ; Dawson, LA; Duxon, MS; Hagan, JJ; Melotto, S; Price, GW; Starr, KR; Upton, N; Watson, JM | 1 |
| Colombo, C; De Ronchi, D; Mandelli, L; Rossini, D; Serretti, A; Tarricone, I; Zanardi, R | 1 |
| Dobkin, RD; Marin, H; Menza, MA | 1 |
| Connor, K; Davidson, JR; Vaishnavi, S | 1 |
| Heerdink, ER; van Dijk, L; Volkers, AC | 1 |
| Haraguchi, K; Hosoi, M; Ieiri, I; Iwata, N; Kinukawa, N; Kobayashi, D; Mine, K; Murakami, Y; Ohtani, H; Ozaki, N; Sawada, Y; Suzuki, T; Tanaka, M | 1 |
| Book, SW; Randall, CL; Randall, PK; Thomas, SE | 1 |
| Cappelleri, JC; Endicott, J; Fehnel, SE; Feltner, D; Harness, J; Morlock, RJ; Williams, VS | 1 |
| Connor, KM; Davidson, JR; Hoge, EA; LeBeau, RT; Pollack, MH; Simon, NM; Worthington, JJ; Zhang, W | 1 |
| Bereza, BG; Einarson, TR; Iskedjian, M; Le Melledo, JM; Walker, JH | 1 |
| Finley, PR | 1 |
| Frost, L; Lal, S | 1 |
| Pyke, RE | 1 |
| Alpert, JE; Fava, M; Maddocks, A; Rosenbaum, JF | 1 |
| Cohn, JB; Dunbar, GC; Fabre, LF; Feighner, JP; Fieve, RR; Mendels, J; Shrivastava, RK | 1 |
| Bray, J; Hunter, BN; Judge, R; Morton, NH; Ravindran, AV | 1 |
| Fonzo, V; Ravizza, L; Rocca, P; Scotta, M; Zanalda, E | 1 |
| Grimes, JB; Hines, A; Labbate, LA; Pollack, MH | 1 |
| Houck, PR; Jacobs, S; Miller, MD; Prigerson, HG; Reynolds, CF; Shear, MK; Zygmont, M | 1 |
| Baker, P; Black, DW; Blum, N; Clancy, G; Gable, J; Monahan, P | 1 |
| Nutt, D | 1 |
| Buysse, DJ; Dew, MA; Kupfer, DJ; Nowell, PD; Reynolds, CF | 1 |
| Farah, A | 1 |
| Ashton, AK | 1 |
| Bell, C; Nutt, D | 1 |
| Nutt, DJ | 1 |
| Liebowitz, MR | 1 |
| Hensley, PL; Nurnberg, HG; Thompson, PM | 1 |
| Westenberg, HG | 1 |
| Baldwin, D; Bobes, J; Faure, M; Scharwächter, I; Stein, DJ | 1 |
| Antonietti, M; Denis, P; Ducrotte, P; Lalaude, O; Leroi, AM; Menard, JF; Touchais, JY | 1 |
| Bellew, KM; Burnham, DB; Goddard, A; Iyengar, MK; McCafferty, JP; Pollack, MH; Zaninelli, R | 1 |
| Baerg, EA; Garland, EJ | 1 |
| Goodwin, W; Hunter, B; Kumar, R; Stein, DJ; Stein, MB | 1 |
| Carpenter, D; Liebowitz, MR; Oakes, R; Pitts, CD; Stein, MB; Tancer, M | 1 |
| Cassano, GB; Puca, F; Scapicchio, PL; Trabucchi, M | 1 |
| Cheer, SM; Goa, KL; Matheson, AJ; Ormrod, D; Wagstaff, AJ | 1 |
| Culpepper, L | 1 |
| Ballas, CA | 1 |
| Bech, P; Lauritzen, L; Lunde, M; Mellerup, ET; Plenge, P | 1 |
| Cohn, JB; Wilcox, CS | 1 |
40 review(s) available for paroxetine and Anxiety Disorders
| Article | Year |
|---|---|
Pharmacological strategies for post-traumatic stress disorder (PTSD): From animal to clinical studies.
Topics: Animals; Anxiety Disorders; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Stress Disorders, Post-Traumatic | 2022 |
Antidepressant discontinuation syndrome: A state-of-the-art clinical review.
Topics: Antidepressive Agents; Anxiety; Anxiety Disorders; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome | 2023 |
Efficacy and safety of lavender essential oil (Silexan) capsules among patients suffering from anxiety disorders: A network meta-analysis.
Topics: Anti-Anxiety Agents; Anxiety Disorders; Capsules; Humans; Lavandula; Lorazepam; Network Meta-Analysis; Oils, Volatile; Paroxetine; Personality Assessment; Plant Oils; Treatment Outcome | 2019 |
Clinical practice guideline on pharmacological and psychological management of adult patients with an anxiety disorder and comorbid substance use.
Topics: Adult; Anxiety Disorders; Desipramine; Humans; Naltrexone; Paroxetine; Substance-Related Disorders | 2022 |
Antidepressants for anxiety disorders in late-life: A systematic review.
Topics: Aged; Antidepressive Agents; Anxiety Disorders; Citalopram; Duloxetine Hydrochloride; Humans; Late Onset Disorders; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline | 2019 |
Female same gender stalking: a brief review of the literature and case report.
Topics: Adult; Anxiety Disorders; Female; Forensic Psychiatry; Homosexuality, Female; Humans; Italy; Paranoid Personality Disorder; Paroxetine; Personality Disorders; Selective Serotonin Reuptake Inhibitors; Stalking; Women | 2013 |
The efficacy of paroxetine and placebo in treating anxiety and depression: a meta-analysis of change on the Hamilton Rating Scales.
Topics: Antidepressive Agents, Second-Generation; Anxiety; Anxiety Disorders; Clinical Trials as Topic; Depression; Double-Blind Method; Humans; Panic Disorder; Paroxetine; Placebos; Psychiatric Status Rating Scales; Severity of Illness Index; Treatment Outcome | 2014 |
Pharmacotherapy for anxiety and comorbid alcohol use disorders.
Topics: Alcohol-Related Disorders; Anxiety; Anxiety Disorders; Buspirone; Comorbidity; Desipramine; Humans; Paroxetine; Phobia, Social; Publication Bias; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Stress Disorders, Post-Traumatic | 2015 |
Don't panic. A guide to tryptophan depletion with disorder-specific anxiety provocation.
Topics: Anxiety; Anxiety Disorders; Humans; Male; Paroxetine; Serotonin; Tryptophan | 2016 |
Generalised anxiety disorder.
Topics: Anxiety Disorders; Citalopram; Cognitive Behavioral Therapy; Double-Blind Method; Humans; Paroxetine; Remission Induction; Sertraline | 2007 |
[Indications for crenotherapy].
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Asthenia; Balneology; Complementary Therapies; Depressive Disorder; Humans; Mental Disorders; Multicenter Studies as Topic; Paroxetine; Randomized Controlled Trials as Topic; Sleep Wake Disorders; Somatoform Disorders | 2009 |
Venlafaxine XR therapy for major depression and anxiety disorders. The clinical implications that its advantages pose.
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety Disorders; Delayed-Action Preparations; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Paroxetine; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 1999 |
[Anxiety disorders: diagnosis and therapy from the family physician's perspective].
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Anxiety Disorders; Behavior Therapy; Cognitive Behavioral Therapy; Cyclohexanols; Diagnosis, Differential; Family Practice; Humans; Panic Disorder; Paroxetine; Practice Guidelines as Topic; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2006 |
Depression and anxiety in oncology: the psychiatrist's perspective.
Topics: Adolescent; Adult; Antidepressive Agents; Anxiety Disorders; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Depressive Disorder; Humans; Medical Oncology; Neoplasms; Paroxetine; Personality Inventory; Prevalence; Psychiatric Status Rating Scales; Psychiatry; Risk Factors; Selective Serotonin Reuptake Inhibitors | 2001 |
Optimizing treatment outcomes for patients with depression and generalized anxiety disorder.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Cyclohexanols; Depressive Disorder, Major; Humans; Paroxetine; Psychotherapy; Randomized Controlled Trials as Topic; Remission Induction; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2002 |
Pharmacotherapy of generalized anxiety disorder.
Topics: Algorithms; Alprazolam; Antidepressive Agents; Antidepressive Agents, Tricyclic; Anxiety Disorders; Benzodiazepines; Buspirone; Combined Modality Therapy; Cyclohexanols; Delayed-Action Preparations; Drug Administration Schedule; Humans; Paroxetine; Psychotherapeutic Processes; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride | 2002 |
Treating generalized anxiety disorder.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Anxiety Disorders; Benzodiazepines; Buspirone; Clinical Trials as Topic; Cognitive Behavioral Therapy; Cyclohexanols; Humans; Imipramine; Paroxetine; Psychotherapy; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; United States; Venlafaxine Hydrochloride | 2003 |
Focus on paroxetine.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety Disorders; Depression; Drug Interactions; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Stress Disorders, Post-Traumatic; Substance Withdrawal Syndrome; Treatment Outcome | 2003 |
Use of paroxetine for the treatment of depression and anxiety disorders in the elderly: a review.
Topics: Aged; Antidepressive Agents, Second-Generation; Anxiety Disorders; Clinical Trials as Topic; Depressive Disorder; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2003 |
In vivo neuroimaging correlates of the efficacy of paroxetine in the treatment of mood and anxiety disorders.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Electroencephalography; Humans; Magnetic Resonance Imaging; Mood Disorders; Paroxetine; Tomography, Emission-Computed, Single-Photon | 2003 |
Efficacy and tolerability of controlled-release paroxetine.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety Disorders; Delayed-Action Preparations; Depressive Disorder, Major; Humans; Paroxetine; Patient Compliance | 2003 |
[Pharmacotherapy of generalized anxiety disorder: state of the art].
Topics: Adolescent; Adult; Age Factors; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety Disorders; Benzodiazepines; Child; Child, Preschool; Cyclohexanols; Double-Blind Method; Humans; Meta-Analysis as Topic; Paroxetine; Placebos; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sleep Initiation and Maintenance Disorders; Time Factors; Venlafaxine Hydrochloride | 2003 |
Paroxetine controlled release.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety Disorders; Delayed-Action Preparations; Depressive Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Drug Tolerance; Female; Humans; Male; Odds Ratio; Paroxetine; Practice Guidelines as Topic; Premenstrual Syndrome; Psychiatric Status Rating Scales | 2004 |
Paroxetine in the treatment of generalised anxiety disorder.
Topics: Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Anxiety Disorders; Benzodiazepines; Buspirone; Delayed-Action Preparations; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2004 |
Cost-effectiveness of psychological and pharmacological interventions for generalized anxiety disorder and panic disorder.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Australia; Cost-Benefit Analysis; Cyclohexanols; Disability Evaluation; Humans; Imipramine; Mental Health Services; Panic Disorder; Paroxetine; Psychotherapy; Selective Serotonin Reuptake Inhibitors; Time Factors; Venlafaxine Hydrochloride | 2004 |
Remission rates in patients with anxiety disorders treated with paroxetine.
Topics: Adolescent; Adult; Aged; Anxiety Disorders; Female; Humans; Longitudinal Studies; Male; Middle Aged; Obsessive-Compulsive Disorder; Panic Disorder; Paroxetine; Phobic Disorders; Placebos; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Stress Disorders, Post-Traumatic; Treatment Outcome | 2004 |
The efficacy of antidepressants for generalized anxiety disorder: a systematic review and meta-analysis.
Topics: Antidepressive Agents; Anxiety Disorders; Cyclohexanols; Female; Humans; Imipramine; Male; Paroxetine; Randomized Controlled Trials as Topic; Treatment Outcome; Venlafaxine Hydrochloride | 2005 |
An evaluation of paroxetine in generalised social anxiety disorder.
Topics: Anxiety Disorders; Clinical Trials as Topic; Drug Evaluation; Humans; Paroxetine; Phobic Disorders | 2005 |
Posttraumatic stress disorder: a state-of-the-science review.
Topics: Adaptation, Psychological; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cognitive Behavioral Therapy; Comorbidity; Cross-Sectional Studies; Depressive Disorder; Hippocampus; Humans; Life Change Events; Paroxetine; Risk Factors; Stress Disorders, Post-Traumatic | 2006 |
Paroxetine response and tolerability among ethnic minority patients with mood or anxiety disorders: a pooled analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anxiety Disorders; Cohort Studies; Depressive Disorder; Ethnicity; Female; Humans; Male; Middle Aged; Minority Groups; Nausea; Paroxetine; Placebos; Selective Serotonin Reuptake Inhibitors; Sleep Initiation and Maintenance Disorders; Survival Analysis; Treatment Outcome | 2005 |
Discontinuation symptoms in depression and anxiety disorders.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Cyclohexanols; Depressive Disorder, Major; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Paroxetine; Substance Withdrawal Syndrome; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride; Withholding Treatment | 2007 |
Remission of generalized anxiety disorder: a review of the paroxetine clinical trials database.
Topics: Adult; Ambulatory Care; Anxiety Disorders; Diagnostic and Statistical Manual of Mental Disorders; Female; Headache; Humans; Longitudinal Studies; Male; Middle Aged; Nausea; Paroxetine; Placebos; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2006 |
Pharmacologic treatment of acute and chronic stress following trauma: 2006.
Topics: Algorithms; Anxiety Disorders; Comorbidity; Depressive Disorder; Disasters; Drug Administration Schedule; Humans; Internet; Paroxetine; Psychotropic Drugs; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Sertraline; Stress Disorders, Post-Traumatic; Stress Disorders, Traumatic, Acute; Survivors; Treatment Outcome | 2006 |
Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions.
Topics: 1-Naphthylamine; Alcoholism; Antidepressive Agents; Anxiety Disorders; Clinical Trials as Topic; Depressive Disorder; Drug Interactions; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 1994 |
Care of depressed patients with anxiety symptoms.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Citalopram; Clinical Trials as Topic; Comorbidity; Depressive Disorder; Fluoxetine; Humans; Mianserin; Mirtazapine; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 1999 |
Update on the diagnosis and treatment of social anxiety disorder.
Topics: Adolescent; Adult; Anxiety Disorders; Cognitive Behavioral Therapy; Comorbidity; Diagnosis, Differential; Female; Humans; Male; Mental Disorders; Mood Disorders; Paroxetine; Phobic Disorders; Quality of Life; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 1999 |
Facing the challenge of social anxiety disorder.
Topics: Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Clinical Trials as Topic; Humans; Monoamine Oxidase Inhibitors; Paroxetine; Selective Serotonin Reuptake Inhibitors | 1999 |
Spotlight on paroxetine in psychiatric disorders in adults.
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety Disorders; Depressive Disorder; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2002 |
Treatment of generalized anxiety disorder.
Topics: Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Agents, Tricyclic; Anxiety Disorders; Benzodiazepines; Buspirone; Clinical Trials as Topic; Cognitive Behavioral Therapy; Cyclohexanols; Follow-Up Studies; Humans; Paroxetine; Psychotherapy; Pyrimidines; Relaxation Therapy; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2002 |
Generalized anxiety disorder in primary care: emerging issues in management and treatment.
Topics: Adaptation, Psychological; Adolescent; Adult; Anxiety Disorders; Cognitive Behavioral Therapy; Comorbidity; Cyclohexanols; Depressive Disorder; Female; Humans; Male; Middle Aged; Paroxetine; Physicians, Family; Prevalence; Primary Health Care; Recurrence; Selective Serotonin Reuptake Inhibitors; Sleep Initiation and Maintenance Disorders; United States; Venlafaxine Hydrochloride | 2002 |
60 trial(s) available for paroxetine and Anxiety Disorders
| Article | Year |
|---|---|
Predictors and trajectories of treatment response to SSRIs in patients suffering from PTSD.
Topics: Anxiety; Anxiety Disorders; Child; Double-Blind Method; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Stress Disorders, Post-Traumatic | 2021 |
Silexan does not cause withdrawal symptoms even when abruptly discontinued.
Topics: Anti-Anxiety Agents; Anxiety Disorders; Double-Blind Method; Humans; Lavandula; Oils, Volatile; Paroxetine; Plant Oils; Substance Withdrawal Syndrome | 2017 |
Treating individuals with social anxiety disorder and at-risk drinking: phasing in a brief alcohol intervention following paroxetine.
Topics: Adaptation, Psychological; Adult; Alcohol Drinking; Antidepressive Agents, Second-Generation; Anxiety; Anxiety Disorders; Combined Modality Therapy; Diagnosis, Dual (Psychiatry); Female; Humans; Male; Paroxetine; Phobic Disorders; Social Behavior Disorders | 2013 |
Difference in remission in a Chinese population with anxious versus nonanxious treatment-resistant depression: a report of OPERATION study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety Disorders; Buspirone; China; Comorbidity; Cyclohexanols; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Female; Humans; Male; Middle Aged; Paroxetine; Remission Induction; Risperidone; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2013 |
Potential benefits of slow titration of paroxetine treatment in an elderly population: eight-week results from a naturalistic setting.
Topics: Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Antidepressive Agents, Second-Generation; Anxiety Disorders; Chi-Square Distribution; Depressive Disorder; Drug Administration Schedule; Female; Humans; Italy; Male; Paroxetine; Patient Dropouts; Psychiatric Status Rating Scales; Time Factors; Treatment Outcome | 2013 |
Lavender oil preparation Silexan is effective in generalized anxiety disorder--a randomized, double-blind comparison to placebo and paroxetine.
Topics: Administration, Oral; Adult; Anti-Anxiety Agents; Antidepressive Agents; Anxiety Disorders; Depression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Germany; Humans; Lavandula; Male; Middle Aged; Oils, Volatile; Paroxetine; Plant Oils; Psychiatric Status Rating Scales; Quality of Life; Remission Induction; Treatment Outcome | 2014 |
High worry severity is associated with poorer acute and maintenance efficacy of antidepressants in late-life depression.
Topics: Aged; Antidepressive Agents; Anxiety Disorders; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Administration Schedule; Factor Analysis, Statistical; Female; Humans; Male; Panic Disorder; Paroxetine; Prospective Studies; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index | 2009 |
Clinical evaluation of the Daily Assessment of Symptoms-Anxiety (DAS-A): a new instrument to assess the onset of symptomatic improvement in generalized anxiety disorder.
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Double-Blind Method; Female; Humans; Lorazepam; Male; Middle Aged; Paroxetine; Sensitivity and Specificity | 2009 |
History of depressive and/or anxiety disorders as a predictor of treatment response: a post hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release in patients with fibromyalgia.
Topics: Adult; Anxiety Disorders; Delayed-Action Preparations; Depressive Disorder; Double-Blind Method; Female; Fibromyalgia; Humans; Male; Middle Aged; Pain Measurement; Paroxetine; Predictive Value of Tests; Treatment Outcome | 2009 |
Clinical features of patients with treatment-emergent suicidal behavior following initiation of paroxetine therapy.
Topics: Adolescent; Adult; Anxiety Disorders; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Paroxetine; Remission Induction; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Suicide, Attempted; Surveys and Questionnaires; Young Adult | 2010 |
Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder.
Topics: Adult; Animals; Anti-Anxiety Agents; Anxiety Disorders; Brain; Dose-Response Relationship, Drug; Gerbillinae; Humans; Male; Neurokinin-1 Receptor Antagonists; Paroxetine; Peptide Fragments; Pyridines; Radioligand Assay; Radionuclide Imaging; Receptors, Neurokinin-1; Stereotyped Behavior; Substance P; Treatment Outcome; Triazoles | 2010 |
Balneotherapy versus paroxetine in the treatment of generalized anxiety disorder.
Topics: Adult; Aged; Anxiety Disorders; Balneology; Female; France; Humans; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2010 |
Heart-focused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitive-behavioral therapy and paroxetine.
Topics: Adult; Aged; Analysis of Variance; Anxiety; Anxiety Disorders; Chest Pain; Cognitive Behavioral Therapy; Double-Blind Method; Fear; Female; Humans; Intention to Treat Analysis; Male; Middle Aged; Pain Measurement; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2010 |
[Efficacy of adepress (paroxetin) in generalized anxiety disorder].
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Female; Humans; Male; Manifest Anxiety Scale; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Young Adult | 2010 |
[Efficacy of escitalopram vs paroxetine on severe depression with associated anxiety: data from the "Boulenger" study].
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Comorbidity; Depressive Disorder, Major; Double-Blind Method; Female; Follow-Up Studies; France; Humans; Male; Middle Aged; Paroxetine; Personality Inventory; Psychometrics | 2010 |
Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Anxiety Disorders; Depressive Disorder, Major; Dose-Response Relationship, Drug; Humans; Male; Mianserin; Mirtazapine; Paroxetine; Prospective Studies; Treatment Outcome; Young Adult | 2011 |
Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Anxiety Disorders; Citalopram; Cyclohexanols; Double-Blind Method; Drug Therapy, Combination; Europe; Female; gamma-Aminobutyric Acid; Humans; Kaplan-Meier Estimate; Least-Squares Analysis; Linear Models; Male; Middle Aged; Odds Ratio; Paroxetine; Placebos; Pregabalin; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Time Factors; Treatment Outcome; United States; Venlafaxine Hydrochloride | 2012 |
Efficacy of Yiqiyangxin Chinese medicine compound combined with cognitive therapy in the treatment of generalized anxiety disorders.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; China; Cognitive Behavioral Therapy; Combined Modality Therapy; Diagnostic and Statistical Manual of Mental Disorders; Drugs, Chinese Herbal; Female; Humans; Male; Medicine, Chinese Traditional; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2012 |
Paroxetine augmentation in patients with generalised social anxiety disorder, non-responsive to mirtazapine or placebo.
Topics: Adrenergic alpha-Antagonists; Adult; Anxiety Disorders; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Sexual Dysfunctions, Psychological; Treatment Outcome | 2011 |
Citalopram treatment of paroxetine-intolerant depressed patients.
Topics: Adult; Anxiety Disorders; Citalopram; Depressive Disorder, Major; Drug Tolerance; Female; Humans; Male; Paroxetine; Prospective Studies; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index | 2002 |
Treatment of depression with comorbid anxiety disorders: differential efficacy of paroxetine versus moclobemide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Anxiety Disorders; Comorbidity; Depressive Disorder; Female; Humans; Male; Middle Aged; Moclobemide; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2003 |
Clinical experience with substance P receptor (NK1) antagonists in depression.
Topics: Antidepressive Agents; Anxiety Disorders; Aprepitant; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Ethers; Female; Humans; Hydrocarbons, Fluorinated; Male; Morpholines; Neurokinin-1 Receptor Antagonists; Paroxetine; Placebos; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Substance P; Treatment Outcome | 2002 |
Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study.
Topics: Adult; Ambulatory Care; Anxiety Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Paroxetine; Placebos; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome | 2003 |
Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder.
Topics: Adolescent; Adult; Aged; Anxiety Disorders; Double-Blind Method; Female; Humans; Male; Middle Aged; Paroxetine; Placebos; Psychiatric Status Rating Scales; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Single-Blind Method; Substance Withdrawal Syndrome; Treatment Outcome | 2003 |
Good treatment outcomes in late-life depression with comorbid anxiety.
Topics: Age of Onset; Aged; Aged, 80 and over; Aging; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Anxiety Disorders; Combined Modality Therapy; Comorbidity; Depressive Disorder; Double-Blind Method; Female; Humans; Middle Aged; Nortriptyline; Paroxetine; Patient Dropouts; Prognosis; Psychotherapy; Treatment Outcome | 2003 |
Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control.
Topics: Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Anxiety Disorders; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; GABA Agonists; Humans; Male; Middle Aged; Nipecotic Acids; Paroxetine; Personality Inventory; Selective Serotonin Reuptake Inhibitors; Sleep; Tiagabine; Treatment Outcome | 2003 |
Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Anxiety Disorders; Control Groups; Cyclohexanols; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Evaluation; Female; Follow-Up Studies; Humans; Male; Middle Aged; Paroxetine; Phobic Disorders; Psychiatric Status Rating Scales; Treatment Outcome; Venlafaxine Hydrochloride | 2004 |
The use of paroxetine and cognitive-behavioral therapy in postpartum depression and anxiety: a randomized controlled trial.
Topics: Adolescent; Adult; Anxiety Disorders; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Depression, Postpartum; Female; Humans; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2004 |
In-patient psychiatric-psychotherapeutic treatment of mothers with a generalized anxiety disorder--does the co-admission of their children influence the treatment results? A prospective, controlled study.
Topics: Adult; Anxiety Disorders; Butyrophenones; Child; Child Care; Child, Hospitalized; Chlorprothixene; Combined Modality Therapy; Drug Therapy, Combination; Female; Hospitals, Psychiatric; Humans; Mathematical Computing; Mother-Child Relations; Mothers; Paroxetine; Patient Admission; Personality Inventory; Prospective Studies; Psychometrics; Psychotherapy; Surveys and Questionnaires; Treatment Outcome | 2004 |
Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline.
Topics: Adult; Anxiety Disorders; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Paroxetine; Practice Guidelines as Topic; Practice Patterns, Physicians'; Prospective Studies; Psychiatric Status Rating Scales; Quality of Life; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2005 |
Do venlafaxine XR and paroxetine equally influence negative and positive affect?
Topics: Adult; Affect; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Paroxetine; Personality Assessment; Regression Analysis; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2005 |
Escitalopram versus paroxetine for social anxiety disorder: an analysis of efficacy for different symptom dimensions.
Topics: Analysis of Variance; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Dose-Response Relationship, Drug; Factor Analysis, Statistical; Humans; Paroxetine; Retrospective Studies; Severity of Illness Index; Single-Blind Method; Treatment Outcome | 2006 |
Does psychological treatment help only those patients with severe irritable bowel syndrome who also have a concurrent psychiatric disorder?
Topics: Adult; Antidepressive Agents; Anxiety Disorders; Child; Child Abuse; Combined Modality Therapy; Comorbidity; Depressive Disorder; Follow-Up Studies; Humans; Irritable Bowel Syndrome; Middle Aged; Outcome and Process Assessment, Health Care; Pain Measurement; Paroxetine; Patient Care Team; Personality Assessment; Personality Inventory; Psychoanalytic Therapy; Psychometrics; Psychophysiologic Disorders; Referral and Consultation; Reproducibility of Results; Selective Serotonin Reuptake Inhibitors; Somatoform Disorders; Treatment Outcome | 2005 |
The effect of pharmacotherapy on personality disorders in panic disorder: a one year naturalistic study.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Comorbidity; Female; Follow-Up Studies; Humans; Male; Middle Aged; Panic Disorder; Paroxetine; Personality Assessment; Personality Disorders; Prospective Studies; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2005 |
Antidepressant treatment outcomes of psychogenic movement disorder.
Topics: Adult; Ambulatory Care; Anxiety Disorders; Chronic Disease; Citalopram; Combined Modality Therapy; Comorbidity; Conversion Disorder; Cyclohexanols; Depressive Disorder; Diagnostic and Statistical Manual of Mental Disorders; Female; Humans; Hypochondriasis; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Psychotherapy; Selective Serotonin Reuptake Inhibitors; Somatoform Disorders; Treatment Outcome; Venlafaxine Hydrochloride | 2005 |
A validation of the 7.5% CO2 model of GAD using paroxetine and lorazepam in healthy volunteers.
Topics: Administration, Inhalation; Adult; Anti-Anxiety Agents; Anxiety Disorders; Carbon Dioxide; Double-Blind Method; Humans; Lorazepam; Male; Paroxetine; Psychiatric Status Rating Scales; Reference Values; Selective Serotonin Reuptake Inhibitors; Time Factors; Treatment Outcome | 2007 |
Comparison of venlafaxine extended release versus paroxetine for treatment of patients with generalized anxiety disorder.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cyclohexanols; Delayed-Action Preparations; Drug Administration Schedule; Female; Headache; Humans; Male; Middle Aged; Nausea; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sweating; Venlafaxine Hydrochloride; Weight Gain | 2006 |
Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study.
Topics: Adult; Aged; Anxiety Disorders; Citalopram; Double-Blind Method; Female; Humans; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2006 |
Effectiveness of a meditation-based stress management program as an adjunct to pharmacotherapy in patients with anxiety disorder.
Topics: Alprazolam; Anti-Anxiety Agents; Anxiety Disorders; Combined Modality Therapy; Fluvoxamine; Humans; Meditation; Paroxetine; Program Development; Self Care; Sertraline; Stress, Psychological; Surveys and Questionnaires | 2007 |
Residual symptoms and recurrence during maintenance treatment of late-life depression.
Topics: Affect; Aged; Antidepressive Agents, Second-Generation; Anxiety Disorders; Combined Modality Therapy; Comorbidity; Depressive Disorder, Major; Female; Follow-Up Studies; Humans; Long-Term Care; Male; Motivation; Paroxetine; Personality Inventory; Psychotherapy; Secondary Prevention; Sleep Wake Disorders; Treatment Outcome | 2007 |
An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Anxiety Disorders; Aripiprazole; Bupropion; Dizziness; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluoxetine; Headache; Humans; Male; Middle Aged; Nausea; Paroxetine; Pilot Projects; Piperazines; Quality of Life; Quinolones; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2007 |
Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety Disorders; Depressive Disorder; Female; Genetic Predisposition to Disease; Humans; Incidence; Japan; Male; Middle Aged; Nausea; Paroxetine; Polymorphism, Genetic; Receptors, Serotonin, 5-HT3; Risk Factors; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index | 2008 |
A complex relationship between co-occurring social anxiety and alcohol use disorders: what effect does treating social anxiety have on drinking?
Topics: Adult; Alcohol Drinking; Anxiety Disorders; Double-Blind Method; Humans; Paroxetine; Patient Compliance; Selective Serotonin Reuptake Inhibitors; Social Behavior | 2008 |
Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings.
Topics: Adult; Anti-Anxiety Agents; Antipsychotic Agents; Anxiety Disorders; Delayed-Action Preparations; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Paroxetine; Personality Inventory; Prospective Studies; Quetiapine Fumarate | 2008 |
Childhood psychopathology retrospectively assessed among adults with early onset major depression.
Topics: 1-Naphthylamine; Adolescent; Adult; Anxiety Disorders; Child; Child Behavior Disorders; Comorbidity; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Imipramine; Male; Mental Disorders; Middle Aged; Paroxetine; Personality Development; Phobic Disorders; Recurrence; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline | 1994 |
A study comparing paroxetine placebo and imipramine in depressed patients.
Topics: Adolescent; Adult; Aged; Anxiety Disorders; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Imipramine; Male; Middle Aged; Paroxetine; Personality Inventory | 1993 |
A double-blind, multicenter study in primary care comparing paroxetine and clomipramine in patients with depression and associated anxiety. Paroxetine Study Group.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Anxiety Disorders; Clomipramine; Comorbidity; Depressive Disorder; Drug Administration Schedule; Female; Headache; Humans; Middle Aged; Nausea; Paroxetine; Patient Dropouts; Placebos; Primary Health Care; Psychiatric Status Rating Scales; Sweating; Treatment Outcome; Tremor; Xerostomia | 1997 |
Paroxetine efficacy in the treatment of generalized anxiety disorder.
Topics: Adolescent; Adult; Analysis of Variance; Anti-Anxiety Agents; Antidepressive Agents; Anxiety Disorders; Benzodiazepines; Chi-Square Distribution; Female; Humans; Imipramine; Male; Middle Aged; Nordazepam; Paroxetine; Treatment Outcome | 1997 |
A post hoc comparison of paroxetine and nortriptyline for symptoms of traumatic grief.
Topics: Adjustment Disorders; Adult; Aged; Antidepressive Agents, Tricyclic; Anxiety Disorders; Depressive Disorder; Drug Administration Schedule; Female; Grief; Humans; Male; Middle Aged; Nortriptyline; Paroxetine; Pilot Projects; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Stress Disorders, Post-Traumatic; Treatment Outcome | 1998 |
Hoarding and treatment response in 38 nondepressed subjects with obsessive-compulsive disorder.
Topics: Age Factors; Age of Onset; Anxiety Disorders; Cognitive Behavioral Therapy; Comorbidity; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Obsessive-Compulsive Disorder; Paroxetine; Personality Inventory; Placebos; Psychiatric Status Rating Scales; Treatment Outcome | 1998 |
Substance-P antagonists: a new treatment for depression?
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Aprepitant; Depressive Disorder; Double-Blind Method; Humans; Morpholines; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Substance P | 1998 |
Paroxetine in the treatment of primary insomnia: preliminary clinical and electroencephalogram sleep data.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety Disorders; Depressive Disorder; Drug Administration Schedule; Electroencephalography; Female; Humans; Male; Middle Aged; Multivariate Analysis; Paroxetine; Personality Inventory; Pilot Projects; Polysomnography; Psychiatric Status Rating Scales; Sleep; Sleep Initiation and Maintenance Disorders; Surveys and Questionnaires; Treatment Outcome | 1999 |
Relief of SSRI-induced sexual dysfunction with mirtazapine treatment.
Topics: Adult; Antidepressive Agents, Tricyclic; Anxiety Disorders; Drug Therapy, Combination; Female; Fluoxetine; Humans; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Sexual Dysfunctions, Psychological; Treatment Outcome | 1999 |
Antidepressant medication change in a clinical treatment setting: a comparison of the effectiveness of selective serotonin reuptake inhibitors.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Tricyclic; Anxiety Disorders; Drug Administration Schedule; Female; Fluoxetine; Humans; Male; Medical Records; Mental Disorders; Middle Aged; Mood Disorders; Paroxetine; Retrospective Studies; Sampling Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 1999 |
Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety Disorders; Double-Blind Method; Female; Humans; Interpersonal Relations; Male; Middle Aged; Paroxetine; Phobic Disorders; Treatment Outcome | 1999 |
Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial.
Topics: Adult; Aged; Ambulatory Care; Anxiety Disorders; Double-Blind Method; Drug Administration Schedule; Female; Health Status; Humans; Male; Middle Aged; Paroxetine; Personality Inventory; Placebos; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome | 2001 |
The selective serotonin reuptake inhibitor paroxetine is effective in more generalized and in less generalized social anxiety disorder.
Topics: Adult; Analysis of Variance; Anxiety Disorders; Confidence Intervals; Double-Blind Method; Female; Humans; Logistic Models; Male; Middle Aged; Odds Ratio; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2001 |
A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder.
Topics: Adolescent; Adult; Aged; Anxiety Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Paroxetine; Placebos; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2002 |
Paroxetine and fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients.
Topics: Affect; Age Factors; Aged; Ambulatory Care; Anxiety Disorders; Cognition; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Male; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Survival Analysis; Treatment Outcome | 2002 |
Paroxetine in major depression: a double-blind trial with imipramine and placebo.
Topics: Adult; Antidepressive Agents; Anxiety Disorders; Depressive Disorder; Double-Blind Method; Female; Humans; Imipramine; Male; Neurotransmitter Uptake Inhibitors; Paroxetine; Piperidines; Placebos; Prospective Studies | 1992 |
49 other study(ies) available for paroxetine and Anxiety Disorders
| Article | Year |
|---|---|
Network and Experimental Pharmacology to Decode the Action of Wendan Decoction Against Generalized Anxiety Disorder.
Topics: Animals; Anxiety Disorders; Corticosterone; Drugs, Chinese Herbal; Interleukin-6; Mice; Molecular Docking Simulation; Paroxetine; Phosphatidylinositol 3-Kinases; Prostaglandins E; Proto-Oncogene Proteins c-akt; Tumor Necrosis Factor-alpha | 2022 |
Cardiac autonomic tone, plasma BDNF levels and paroxetine response in newly diagnosed patients of generalised anxiety disorder.
Topics: Adult; Anxiety Disorders; Autonomic Nervous System; Biomarkers; Brain-Derived Neurotrophic Factor; Electrocardiography; Heart Rate; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2020 |
Observational multicenter study of efficacy of paroxetine filmcoated tablet in the treatment of anxiety disorder.
Topics: Adult; Anxiety; Anxiety Disorders; Cohort Studies; Female; Humans; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Tablets; Treatment Outcome | 2018 |
Early-life exposure to the SSRI paroxetine exacerbates depression-like behavior in anxiety/depression-prone rats.
Topics: Amygdala; Animals; Animals, Newborn; Anxiety Disorders; Depressive Disorder; Disease Models, Animal; Exploratory Behavior; Female; Gene Expression Regulation, Developmental; Genetic Predisposition to Disease; Hippocampus; Male; Maternal Behavior; Paroxetine; Pregnancy; Prenatal Exposure Delayed Effects; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors | 2015 |
Persistent benefits of slow titration of paroxetine in a six-month follow-up.
Topics: Aged; Aged, 80 and over; Anxiety Disorders; Comorbidity; Depressive Disorder, Major; Female; Follow-Up Studies; Humans; Male; Outcome Assessment, Health Care; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2015 |
[Thermotherapy: the treatment of generalized anxiety disorder].
Topics: Anxiety Disorders; Humans; Hyperthermia, Induced; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2008 |
Observation of treatment of depression in primary care setting in first week - what happens in first week of treatment with antidepressants?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Anxiety Disorders; Depressive Disorder; Diagnosis, Differential; Family Practice; Female; Humans; Male; Middle Aged; Paroxetine; Patient Acceptance of Health Care; Patient Education as Topic; Personality Inventory; Primary Health Care; Slovenia | 2008 |
A pilot study of the effects of chronic paroxetine administration on hippocampal N-acetylaspartate in generalized anxiety disorder.
Topics: Adult; Anxiety Disorders; Aspartic Acid; Creatine; Female; Hippocampus; Humans; Male; Middle Aged; Neurons; Paroxetine; Pilot Projects; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Time Factors; Treatment Outcome | 2010 |
Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cytochrome P-450 CYP2D6; Depressive Disorder; Drug Administration Schedule; Female; Genetic Predisposition to Disease; Humans; Male; Middle Aged; Paroxetine; Polymorphism, Genetic; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2C; Receptors, Serotonin; Receptors, Serotonin, 5-HT3; Risk Factors; Serotonin Plasma Membrane Transport Proteins; Substance Withdrawal Syndrome | 2010 |
Advancing bipolar disorder: key lessons from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).
Topics: Anticonvulsants; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Bupropion; Combined Modality Therapy; Comorbidity; Database Management Systems; Humans; Inositol; Lamotrigine; Multicenter Studies as Topic; Paroxetine; Psychotherapy, Brief; Randomized Controlled Trials as Topic; Recurrence; Research Design; Risperidone; Smoking; Substance-Related Disorders; Suicide; Treatment Outcome; Triazines; United States; Vitamin B Complex | 2010 |
Psychometric evaluation of a visual analog scale for the assessment of anxiety.
Topics: Adult; Anxiety Disorders; Female; Humans; Lorazepam; Male; Middle Aged; Paroxetine; Psychometrics; Randomized Controlled Trials as Topic; Reproducibility of Results; Time Factors | 2010 |
Pindolol potentiates the panicolytic effect of paroxetine in the elevated T-maze.
Topics: Adrenergic beta-Antagonists; Animals; Antidepressive Agents, Second-Generation; Anxiety Disorders; Drug Combinations; Drug Interactions; Male; Panic Disorder; Paroxetine; Pindolol; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors | 2010 |
Angular cheilitis after paroxetine treatment.
Topics: Adult; Anxiety Disorders; Cheilitis; Citalopram; Diagnosis, Differential; Drug Eruptions; Drug Substitution; Female; Follow-Up Studies; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2012 |
How to use an article reporting a multiple treatment comparison meta-analysis.
Topics: Anxiety Disorders; Bias; Evidence-Based Medicine; Humans; Meta-Analysis as Topic; Middle Aged; Paroxetine; Randomized Controlled Trials as Topic; Research Design; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2012 |
The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Antidepressive Agents; Antidiuretic Hormone Receptor Antagonists; Anxiety Disorders; Citalopram; Clinical Trials, Phase II as Topic; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Indoles; Male; Middle Aged; Multicenter Studies as Topic; Paroxetine; Pyrrolidines; Randomized Controlled Trials as Topic; Recurrence; Treatment Outcome; Young Adult | 2012 |
Acute effects of amperozide and paroxetine on social cohesion in male conspecifics.
Topics: Animals; Anxiety Disorders; Behavior, Animal; Dose-Response Relationship, Drug; Male; Paroxetine; Piperazines; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Sex Factors; Social Behavior; Social Behavior Disorders; Treatment Outcome | 2002 |
Angela.
Topics: Adult; Advertising; Anxiety Disorders; Attitude to Health; Drug Industry; Female; Humans; Paroxetine; Physician-Patient Relations; Psychiatry; Self Medication | 2002 |
Reduction of hypothalamic vasopressinergic hyperdrive contributes to clinically relevant behavioral and neuroendocrine effects of chronic paroxetine treatment in a psychopathological rat model.
Topics: Animals; Anxiety Disorders; Disease Models, Animal; Hypothalamus; Male; Neurosecretory Systems; Paroxetine; Rats; RNA, Messenger; Species Specificity; Vasopressins | 2003 |
Paroxetine-induced somnambulism.
Topics: Anxiety Disorders; Depressive Disorder; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Somnambulism | 2003 |
Advancing the treatment of mood and anxiety disorders: the first 10 years' experience with paroxetine.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Humans; Mood Disorders; Paroxetine | 2003 |
Paroxetine treatment of mood and anxiety disorders in children and adolescents.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Anxiety Disorders; Child; Depressive Disorder, Major; Humans; Mood Disorders; Paroxetine; Phobic Disorders | 2003 |
Time to antidepressant discontinuation: a comparison of controlled-release paroxetine and immediate-release selective serotonin-reuptake inhibitors.
Topics: Antidepressive Agents; Anxiety Disorders; Delayed-Action Preparations; Demography; Depressive Disorder; Dose-Response Relationship, Drug; Female; Humans; Insurance Claim Reporting; Male; Managed Care Programs; Massachusetts; Paroxetine; Proportional Hazards Models; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Survival Analysis; Treatment Outcome | 2003 |
Drugs vs. talk therapy: 3,079 readers rate their care for depression and anxiety.
Topics: Antidepressive Agents; Anxiety; Anxiety Disorders; Bupropion; Citalopram; Cyclohexanols; Depression; Drug Therapy; Fluoxetine; Humans; Paroxetine; Patient Satisfaction; Primary Health Care; Psychiatry; Psychology; Psychotherapy; Selective Serotonin Reuptake Inhibitors; Sertraline; Social Work | 2004 |
Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram.
Topics: Adolescent; Adult; Age Factors; Antidepressive Agents; Anxiety Disorders; Citalopram; Cohort Studies; Depression; Female; Humans; Male; Middle Aged; Paroxetine; Patient Compliance; Patient Dropouts; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; Stress Disorders, Post-Traumatic | 2005 |
Interpersonal psychotherapy for depression with panic spectrum symptoms: a pilot study.
Topics: Anxiety Disorders; Citalopram; Depressive Disorder, Major; Female; Fluoxetine; Humans; Interpersonal Relations; Male; Panic Disorder; Paroxetine; Pilot Projects; Problem Solving; Psychotherapy; Quality of Life; Selective Serotonin Reuptake Inhibitors | 2005 |
Differences in total medical costs across the SSRIs for the treatment of depression and anxiety.
Topics: Adolescent; Adult; Anxiety Disorders; Benchmarking; Comorbidity; Databases as Topic; Depressive Disorder; Drug Utilization Review; Female; Health Care Costs; Humans; Male; Managed Care Programs; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2005 |
Adherence to paroxetine CR compared with paroxetine IR in a Medicare-eligible population with anxiety disorders.
Topics: Aged; Anxiety Disorders; Benchmarking; Comorbidity; Databases as Topic; Delayed-Action Preparations; Depressive Disorder; Female; Humans; Male; Managed Care Programs; Medicare; Paroxetine; Patient Compliance; Selective Serotonin Reuptake Inhibitors | 2005 |
Reexamining paroxetine and cognitive-behavioral therapy in postpartum depression and anxiety.
Topics: Anxiety Disorders; Bias; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Depression, Postpartum; Female; Humans; Paroxetine; Patient Selection; Pregnancy; Puerperal Disorders; Randomized Controlled Trials as Topic; Research Design; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2005 |
Predictors of symptom resolution in panic disorder after one year of pharmacological treatment: a naturalistic study.
Topics: Adult; Agoraphobia; Anxiety Disorders; Citalopram; Diagnostic and Statistical Manual of Mental Disorders; Female; Follow-Up Studies; Humans; Male; Panic Disorder; Paroxetine; Prospective Studies; Remission Induction; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index | 2006 |
Comparison of first refill rates among users of sertraline, paroxetine, and citalopram.
Topics: Adolescent; Adult; Anxiety Disorders; Citalopram; Cohort Studies; Cost Sharing; Databases, Factual; Depression; Drug Prescriptions; Female; Humans; Logistic Models; Male; Middle Aged; Paroxetine; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; United States | 2006 |
Cost-effectiveness analysis of escitalopram compared with paroxetine in treatment of generalized anxiety disorder in the United Kingdom.
Topics: Anxiety Disorders; Citalopram; Cost-Benefit Analysis; Decision Support Techniques; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Time Factors; United Kingdom | 2006 |
SB-649915-B, a novel 5-HT1A/B autoreceptor antagonist and serotonin reuptake inhibitor, is anxiolytic and displays fast onset activity in the rat high light social interaction test.
Topics: Animals; Anti-Anxiety Agents; Anxiety Disorders; Behavior, Animal; Benzoxazines; Brain; Callithrix; Drug Synergism; Male; Motor Activity; Paroxetine; Piperidines; Quinolines; Rats; Rats, Sprague-Dawley; Reaction Time; Receptor, Serotonin, 5-HT1A; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin 5-HT1 Receptor Agonists; Serotonin Antagonists; Social Behavior; Vocalization, Animal | 2007 |
Antidepressant response in the elderly.
Topics: Adult; Age Factors; Aged; Antidepressive Agents; Anxiety Disorders; Bipolar Disorder; Cyclohexanols; Depressive Disorder, Major; Female; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Personality Inventory; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride | 2007 |
An abbreviated version of the Connor-Davidson Resilience Scale (CD-RISC), the CD-RISC2: psychometric properties and applications in psychopharmacological trials.
Topics: Antidepressive Agents; Anxiety Disorders; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder, Major; Fluoxetine; Humans; Kava; Mianserin; Mirtazapine; Paroxetine; Psychometrics; Sertraline; Stress Disorders, Post-Traumatic; Surveys and Questionnaires; Venlafaxine Hydrochloride | 2007 |
Antidepressant use and off-label prescribing in children and adolescents in Dutch general practice (2001-2005).
Topics: Adolescent; Adrenergic Uptake Inhibitors; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Child; Cyclohexanols; Depressive Disorder; Drug Labeling; Drug Prescriptions; Drug Utilization; Family Practice; Female; Humans; Imipramine; Male; Netherlands; Nocturnal Enuresis; Paroxetine; Practice Patterns, Physicians'; Selective Serotonin Reuptake Inhibitors; Tension-Type Headache; Time Factors; Venlafaxine Hydrochloride | 2007 |
Development and evaluation of the Daily Assessment of Symptoms - Anxiety (DAS-A) scale to evaluate onset of symptom relief in patients with generalized anxiety disorder.
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Female; Focus Groups; Health Status; Humans; Kaplan-Meier Estimate; Lorazepam; Male; Paroxetine; Personality Inventory; Predictive Value of Tests; Psychometrics; Regression Analysis; Reproducibility of Results; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2008 |
Cost-effectiveness of escitalopram for generalized anxiety disorder in Canada.
Topics: Adolescent; Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Anxiety Disorders; Canada; Chronic Disease; Citalopram; Confidence Intervals; Cost of Illness; Cost Savings; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Health Care Costs; Humans; Male; Middle Aged; Models, Economic; Monte Carlo Method; Paroxetine; Primary Health Care; Sensitivity and Specificity; Severity of Illness Index | 2008 |
Shock-like sensations after discontinuation of selective serotonin reuptake inhibitors.
Topics: 1-Naphthylamine; Adult; Anxiety Disorders; Electric Injuries; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sensation Disorders; Sertraline; Substance Withdrawal Syndrome | 1995 |
Paroxetine withdrawal syndrome.
Topics: Adult; Anorexia; Anxiety Disorders; Depressive Disorder; Diarrhea; Dizziness; Female; Humans; Nausea; Paroxetine; Substance Withdrawal Syndrome | 1995 |
Paxil (paroxetine) lifts depression, lowers associated anxiety symptoms.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Depressive Disorder; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors | 1997 |
Bupropion treatment of serotonin reuptake antidepressant-associated sexual dysfunction.
Topics: 1-Naphthylamine; Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Anxiety Disorders; Bupropion; Drug Therapy, Combination; Female; Fluoxetine; Humans; Libido; Male; Middle Aged; Mood Disorders; Pain Measurement; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Sexual Behavior; Sexual Dysfunctions, Psychological; Treatment Outcome | 1997 |
Sildenafil treatment of paroxetine-induced anorgasmia in a woman.
Topics: Anxiety Disorders; Female; Humans; Orgasm; Paroxetine; Phosphodiesterase Inhibitors; Piperazines; Purines; Selective Serotonin Reuptake Inhibitors; Sex Factors; Sexual Dysfunctions, Psychological; Sildenafil Citrate; Sulfones; Treatment Outcome | 1999 |
Paroxetine and its uses in psychiatry.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Depression; Drug Interactions; Humans; Mental Disorders; Obsessive-Compulsive Disorder; Panic Disorder; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sleep Wake Disorders | 1999 |
Prolonged stationary colonic motility recording in seven patients with severe constipation secondary to antidepressants.
Topics: Adult; Amitriptyline; Antidepressive Agents; Anxiety Disorders; Cathartics; Cholinergic Antagonists; Clomipramine; Colon; Colonoscopy; Constipation; Depressive Disorder; Eating; Fecal Impaction; Female; Gastrointestinal Motility; Humans; Male; Manometry; Maprotiline; Middle Aged; Mood Disorders; Muscle Contraction; Paroxetine; Selective Serotonin Reuptake Inhibitors; Thiazepines; Viloxazine | 2000 |
[Generalized social anxiety disorders: recognized too rarely].
Topics: Anxiety Disorders; Humans; Paroxetine; Phobic Disorders; Randomized Controlled Trials as Topic; Treatment Outcome | 1999 |
Amotivational syndrome associated with selective serotonin reuptake inhibitors in children and adolescents.
Topics: Adolescent; Anxiety Disorders; Child; Depressive Disorder; Female; Fluoxetine; Humans; Male; Motivation; Obsessive-Compulsive Disorder; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2001 |
[Depression and anxiety. Broad spectrum SSRI to control both].
Topics: Anxiety Disorders; Comorbidity; Depressive Disorder; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2001 |
Surprising results in the study of paroxetine for generalized anxiety disorder.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Clinical Trials as Topic; Humans; Paroxetine; Placebo Effect; Placebos; Psychiatric Status Rating Scales; Psychopharmacology; Treatment Outcome | 2002 |
Platelet paroxetine binding in alcoholics.
Topics: Adult; Aged; Alcoholism; Anxiety Disorders; Binding Sites; Blood Platelets; Depressive Disorder; Female; Humans; Male; Middle Aged; Paroxetine; Receptors, Serotonin | 1992 |